- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Dayna Johnson Discusses Link Between Poor Sleep, Cardiovascular Health
In this interview from SLEEP 2023, Dayna Johnson, PhD, MPH, MSW, MS, addresses the various pathways through which cardiovascular health is adversely affected by suboptimal sleep health.
There are different pathways by which sleep contributes to cardiovascular disease, and these include hormone secretion, which connects to diabetes, and sympathetic nervous activity, which can increase blood pressure; sleep health is connected through these pathways to both traditional cardiovascular risk factors and total cardiovascular disease, explains Dayna Johnson, PhD, MPH, MSW, MS, assistant professor of epidemiology at the Rollins School of Public Health at Emory University in this interview from SLEEP 2023.
Transcript
How are poor sleep health and poor cardiovascular health interrelated?
We've seen a lot of progress in this area. In the last year, the American Heart Association has changed their platform, which was previously the Life’s Simple 7 to Life’s Essential 8—so really recognizing how important sleep is to cardiovascular health. So in the epidemiologic literature, we see that people who have a shorter sleep duration, poor sleep quality, they have a higher prevalence of hypertension, also diabetes, cardiovascular disease, and a higher rate of mortality.
There's different pathways by which sleep can contribute to cardiovascular disease. Some of the pathways include hormone secretion, so around insulin and glucose secretion, which connects to diabetes, which is associated with total cardiovascular disease. And then there's also pathways through the sympathetic nervous activity—which can lead to an increase in blood pressure—also is related to hypertension.
These different dimensions of sleep health are connected through these different pathways to traditional cardiovascular risk factors and to total cardiovascular disease.
AXS25: Health Policy, Drug Costs, and AI Highlights From the Conference
May 6th 2025Asembia’s AXS25 Summit covered a variety of relevant topics in the pharmaceutical industry, from the effects of the new administration to how artificial intelligence (AI) is reshaping the patience experience.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR
May 5th 2025KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More
